+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Diabetic Nephropathy Market 2018-2022 - Product Image

Global Diabetic Nephropathy Market 2018-2022

  • ID: 4721372
  • Report
  • December 2018
  • Region: Global
  • 98 pages
  • TechNavio
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca
  • Merck
  • Sanofi
  • MORE
Rise in incidence of diabetes to push growth in the market. Globally, there has been a rise in the incidence and prevalence of diabetes, which has resulted in the occurrence of chronic kidney disease in patients. The analysts have predicted that the diabetic nephropathy market will register a CAGR of almost 34% by 2022.

Market Overview

Increasing incidence of diabetic nephropathy among diabetic patients

The incidence of diabetic nephropathy was observed to be much higher in freshly diagnosed cases of type 2 diabetes patients. The factors associated with the rise of incidence of nephropathy are hypertension, hypercholesterolemia, and obesity.

Growing economic burden of diabetic nephropathy

Diabetic nephropathy is a complication associated with diabetes mellitus. The cost associated with diabetic nephropathy increases gradually with the progression of disease due to the associated cost drivers such as dialysis and hospitalization.

For the detailed list of factors that will drive and challenge the growth of the diabetic nephropathy market during the 2018-2022, view this report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies including Techman-Head Group and Brackett Aircraft Company, the competitive environment is quite intense. Factors such as the increasing incidence of diabetic nephropathy among diabetic patients and the rise in incidence of diabetes, will provide considerable growth opportunities to diabetic nephropathy manufactures. AstraZeneca, Merck, and Sanofi are some of the major companies covered in this report.
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Merck
  • Sanofi
  • MORE
PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE
  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis
PART 05: PIPELINE ANALYSIS
  • Pipeline analysis
PART 06: MARKET SIZING
  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022
PART 07: FIVE FORCES ANALYSIS
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition
PART 08: MARKET SEGMENTATION BY DRUG CLASS
  • Segmentation by drug class
  • Comparison by drug class
  • ARBs - Market size and forecast 2017-2022
  • ACE inhibitors - Market size and forecast 2017-2022
  • Others - Market size and forecast 2017-2022
  • Market opportunity by drug class
PART 09: MARKET SEGMENTATION BY TYPE OF DISEASE
  • Segmentation by type of disease
PART 10: CUSTOMER LANDSCAPE

PART 11: REGIONAL LANDSCAPE
  • Geographical segmentation
  • Regional comparison
  • Americas - Market size and forecast 2017-2022
  • EMEA - Market size and forecast 2017-2022
  • APAC - Market size and forecast 2017-2022
  • Market opportunity
PART 12: DECISION FRAMEWORK

PART 13: DRIVERS AND CHALLENGES
  • Market drivers
  • Market challenges
PART 14: MARKET TRENDS
  • Rise in incidence of diabetes
  • Increase in diabetic nephropathy-related cardiovascular mortality and end-stage renal disease
  • Multidisciplinary approach for the management of diabetic nephropathy
PART 15: VENDOR LANDSCAPE
  • Overview
  • Landscape disruption
PART 16: VENDOR ANALYSIS
  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca
  • Merck
  • Sanofi
PART 17: APPENDIX
  • List of abbreviations
List of Exhibits
Exhibit 01: Parent market
Exhibit 02: Global metabolic disorder drugs market
Exhibit 03: Market characteristics
Exhibit 04: Market segments
Exhibit 05: Pipeline drugs for diabetic nephropathy under Phase III stage of development
Exhibit 06: Market definition - Inclusions and exclusions checklist
Exhibit 07: Market size 2017
Exhibit 08: Validation techniques employed for market sizing 2017
Exhibit 09: Global - Market size and forecast 2017-2022 ($ mn)
Exhibit 10: Global - Year-over-year growth 2018-2022 (%)
Exhibit 11: Five forces analysis 2017
Exhibit 12: Five forces analysis 2022
Exhibit 13: Bargaining power of buyers
Exhibit 14: Bargaining power of suppliers
Exhibit 15: Threat of new entrants
Exhibit 16: Threat of substitutes
Exhibit 17: Threat of rivalry
Exhibit 18: Drug class - Market share 2017-2022 (%)
Exhibit 19: Comparison by drug class
Exhibit 20: ARBs - Market size and forecast 2017-2022 ($ mn)
Exhibit 21: ARBs - Year-over-year growth 2018-2022 (%)
Exhibit 22: ACE inhibitors - Market size and forecast 2017-2022 ($ mn)
Exhibit 23: ACE inhibitors - Year-over-year growth 2018-2022 (%)
Exhibit 24: Others - Market size and forecast 2017-2022 ($ mn)
Exhibit 25: Others - Year-over-year growth 2018-2022 (%)
Exhibit 26: Market opportunity by drug class
Exhibit 27: Customer landscape
Exhibit 28: Global - Market share by geography 2017-2022 (%)
Exhibit 29: Regional comparison
Exhibit 30: Americas - Market size and forecast 2017-2022 ($ mn)
Exhibit 31: Americas - Year-over-year growth 2018-2022 (%)
Exhibit 32: Top 3 countries in Americas
Exhibit 33: EMEA - Market size and forecast 2017-2022 ($ mn)
Exhibit 34: EMEA - Year-over-year growth 2018-2022 (%)
Exhibit 35: Top 3 countries in EMEA
Exhibit 36: APAC - Market size and forecast 2017-2022 ($ mn)
Exhibit 37: APAC - Year-over-year growth 2018-2022 (%)
Exhibit 38: Top 3 countries in APAC
Exhibit 39: Market opportunity
Exhibit 40: Pipeline drugs in various stages of clinical trials for diabetic nephropathy
Exhibit 41: Vendor landscape
Exhibit 42: Landscape disruption
Exhibit 43: Vendors covered
Exhibit 44: Vendor classification
Exhibit 45: Market positioning of vendors
Exhibit 46: AstraZeneca - Overview
Exhibit 47: AstraZeneca - Business segments
Exhibit 48: AstraZeneca - Organizational developments
Exhibit 49: AstraZeneca - Geographic focus
Exhibit 50: AstraZeneca - Key offerings
Exhibit 51: Merck - Overview
Exhibit 52: Merck - Business segments
Exhibit 53: Merck - Organizational developments
Exhibit 54: Merck- Geographic focus
Exhibit 55: Merck - Segment focus
Exhibit 56: Merck - Key offerings
Exhibit 57: Sanofi - Overview
Exhibit 58: Sanofi - Business segments
Exhibit 59: Sanofi - Organizational developments
Exhibit 60: Sanofi - Geographic focus
Exhibit 61: Sanofi - Segment focus
Exhibit 62: Sanofi - Key offerings
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4

FEATURED COMPANIES

  • AstraZeneca
  • Merck
  • Sanofi
  • MORE
Global Diabetic Nephropathy Market 2018-2022

The analyst recognizes the following companies as the key players in the global diabetic nephropathy market: AstraZeneca, Merck, and Sanofi.

Commenting on the report, an analyst from the research team said: “The latest trend gaining momentum in the market is the rise in incidence of diabetes.”

According to the report, one of the major drivers for this market is the increasing incidence of diabetic nephropathy among diabetic patients.

Further, the report states that one of the major factors hindering the growth of this market is the growing economic burden of diabetic nephropathy.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 4
  • AstraZeneca
  • Merck
  • Sanofi
Note: Product cover images may vary from those shown
Adroll
adroll